N
Intellia Therapeutics D
D
NTLA
13.595
USD
0.83
(6.50%)
مغلق
حجم التداول
183,411
الربح لكل سهم
-5
العائد الربحي
-
P/E
-3
حجم السوق
1,408,216,241
الأخبار المقالات
العنوان: Intellia Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.